Internal Contact Information
Dr. Frelinger's career has been focused on the production of antigen specific T-cells. While much of this has been directed at virus and bacterial antigens, he has used approaches to directly inform immunotherapy in cancer. Dr. Frelinger published a series of papers that follow the development of the concept of an altered peptide ligand from an observation in HIV through its confirmation with the breast tumor epitope Her2/neu into humanized ice and then into a clinical trial. He has been and continues to be interested in moving basic science from the fundamental to the practical.